Sharp Services, a leader in pharmaceutical packaging, clinical trial services, and sterile manufacturing, has announced a $100 million investment across its global facility network to address increasing market demand for established and new medicines. This strategic financial commitment underscores the growing need for enhanced production capabilities in the pharmaceutical sector.
With six GMP facilities in the US and three in Europe, Sharp is well-positioned to provide comprehensive clinical and commercial solutions worldwide. The expansion of services across its facility network will enhance the company’s ability to meet the evolving needs of its clients, particularly in the wake of rising demand for injectable products.
Kevin Orfan, President & CEO of Sharp, emphasized the importance of these investments in reinforcing the company’s role as a trusted partner in the pharmaceutical industry. The new capacity will specifically address the increasing market demand for pre-filled syringes and autoinjectors, with facilities in the Netherlands and Belgium undergoing significant upgrades to accommodate this need.
In addition to expanding its injectable capacity, Sharp is enhancing its Allentown campus with new assembly lines and packaging equipment, which will support both existing and new products. This comprehensive investment strategy not only aims to bolster production capabilities but also positions Sharp to capitalize on emerging opportunities in the pharmaceutical landscape.
Overall, these developments reflect Sharp’s commitment to advancing its service offerings and operational efficiency, ensuring that it remains a key player in the global pharmaceutical supply chain.
Start your 7-day trial and see what the database can do →
